Table 2.
Neuroimaging and Electroencephalography Results in Patients with COVID-19
| Type of Testing and Results | n (%) |
|---|---|
| Computed tomography | |
| Deep lobar hypoattenuation | 6 (22.2) |
| Deep supratentorial hypodensity | 14 (51.9) |
| Caudate head | 1 (3.7) |
| Corona radiata | 6 (22.2) |
| Globus pallidus | 2 (7.4) |
| Internal capsule | 5 (18.5) |
| Subacute ischemic stroke | 4 (14.8) |
| Subcortical parenchymal hematoma | 3 (11.1) |
| Magnetic resonance imaging | |
| DWI | 5 (18.5) |
| Ep2d_tra_hemo | 1 (3.7) |
| FLAIR | 6 (22.2) |
| MP-RAGE | 1 (3.7) |
| SWI | 3 (11.1) |
| Electroencephalography | |
| Generalized encephalopathy | 11 (40.1) |
| NCSE | 1 (3.7) |
| Vascular imaging | |
| Focal stenosis—ICA terminus | 3 (11.1) |
| Large vessel occlusion—PCA P2B | 1 (3.7) |
N denotes total number of patients with documentation of said finding, and % is relative to all critical patients with COVID-19 with clear neurologic involvement.
COVID-19, coronavirus disease 2019; DWI, diffusion-weighted imaging, ep2d_tra_hemo, gradient echo imaging; FLAIR, fluid-attenuated inversion recovery; MP-RAGE, magnetization prepared–rapid gradient echo; SWI, susceptibility-weighed imaging; NCSE, nonconvulsive status epilepticus; ICA, internal carotid artery; PCA, posterior cerebral artery.